前收市價 | 8.50 |
開市 | 無 |
買盤 | 5.20 |
賣出價 | 9.00 |
拍板 | 22.00 |
到期日 | 2025-03-21 |
今日波幅 | 8.50 - 8.50 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 2 |
With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the best gene editing stocks to buy. That’s because unlike more standard therapeutics such as antibiotics, antivirals and vaccines gene editing is a permanent solution most of the time. It changes the base instructions of the human body for how the body is maintained and protected. As a result, several h
Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin deficiency.
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.